Viewing Study NCT02729961


Ignite Creation Date: 2025-12-24 @ 12:10 PM
Ignite Modification Date: 2025-12-27 @ 9:43 PM
Study NCT ID: NCT02729961
Status: WITHDRAWN
Last Update Posted: 2019-10-10
First Post: 2016-03-29
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Sponsor: University of Washington
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anaplastic Large Cell Lymphoma, ALK-Positive View
None CD30-Positive Neoplastic Cells Present View
None Systemic Anaplastic Large Cell Lymphoma View
Keywords: